Evotec SE
corporate_fare Company Profile
Evotec SE (NASDAQ:EVO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for EVO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for EVO spans 6-K, SCHEDULE 13D/A, 20-F, SCHEDULE 13D.
Recent high-impact activity:
- Evotec Posts Final 9M 2026 Results, Reaffirms Guidance and Details €1B 2030 Framework
- Evotec Q3 Revenue Hits €164.9M as EBITDA Loss Narrows 89%, Reaffirms 2026 Guidance
- Mubadala Exits Evotec SE, Selling Entire Stake in Block Trade
- Evotec 9M Revenue Tops Expectations; FY26 Guidance Reaffirmed
- Evotec Forms Oncology Research Pact with Plectonic for Next-Gen T-Cell Therapies
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 76,498 shares in EVO as of the October 15, 2026 settlement, a 246.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 6, 2026, 40.7% of EVO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
EVO files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.